Drug Metabolism and Pharmacokinetics

Papers
(The H4-Index of Drug Metabolism and Pharmacokinetics is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Prediction and validation of fetal exposure to dual BCRP/P-GP drug substrates using the proteomics informed efflux ratio-relative expression factor (ER-REF) approach and PBPK modeling and simulation184
Corrigendum to “Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration” [Drug Metabol Pharmacokinet 41 (2021) 100408]102
Effects of genetic polymorphisms of canine CYP2D15 on in vitro hepatic metabolism and in vivo pharmacokinetics of celecoxib, and the strategy for the accurate prediction of human pharmacokinetics61
The spectrum of hepatic clearance models, from old to new24
Monocarboxylate transporter 10: substrate-dependent mode of transport24
Development of an in vitro metabolism approach of acrylamide covalent drugs for predicting metabolism and disposition in human22
The mass balance recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: radiosynthesis of [14c]-orvepitant15
Clinical studies on pharmacogenomics and DDIS involving drug transporters15
Beyond non-human primates: Transgenics and PBPK models for predicting the human PK of protein therapeutics15
Development of a new assay system for bladder cancer using interactions between cytochromes P450 and serum14
Formation of reactive metabolites of benzbromarone in humanized-liver mice14
Dual kinetics of OATP2B1: Inhibitory potency and pH-dependence of OATP2B1 inhibitors13
Applications of model simulation in pharmacological fields and the problems of theoretical reliability12
Double Trap Interface: A novel gas interface for high throughput analysis of biomedical samples by AMS12
In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition12
0.11821794509888